Elanco Animal Health (ELAN) Peer Comparison
$21.77
$-0.62
(-2.77%)
As on 01-Oct-2026 16:00EDT
Market cap
$11,361 Mln
Revenue (TTM)
$5,020 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Edit
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
11,361 | 12,818 | 12,550 | 12,122 | 10,219 |
Revenue ($ Mln) |
5,020 | 692 | 831 | 432 | 777 |
Net Profit ($ Mln) |
-199.00 | -696.24 | 54.90 | -136.72 | -191.64 |
Net Margin (%) |
-3.96 | -100.64 | 6.61 | -31.66 | -24.68 |
RoE (%) |
-3.03 | -- | 8.11 | -30.32 | -223.36 |
Price to Earnings |
-- | -- | 258.00 | -- | -- |
Price-To-Book |
1.73 | 123.68 | 18.00 | 23.58 | 121.64 |
Income Statement ($ Mln)
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5,020.00 | 691.84 | 830.81 | 431.80 | 776.57 |
|
Cost of Revenue
|
2,380.00 | 47.45 | 14.09 | 207.41 | 52.53 |
|
Gross Profit
|
2,050.00 | 473.81 | 748.43 | 191.00 | 591.02 |
|
Operating Expenses
|
2,178.00 | 1,187.86 | 810.32 | 362.16 | 912.58 |
|
Operating Profit (EBIT)
|
462.00 | -543.47 | 6.41 | -137.77 | -188.54 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-166.00 | -706.17 | 26.37 | -135.85 | -191.09 |
|
Provision for Tax
|
33.00 | -7.73 | -35.26 | 0.24 | 0.56 |
|
Profit after Tax (Net Income)
|
-199.00 | -696.24 | 54.90 | -136.72 | -191.64 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
6,588.00 | -2,515.22 | 705.78 | 445.74 | 83.30 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
5,121.00 | 2,832.54 | 29.12 | 106.44 | 217.70 |
|
Current Liabilities
|
1,852.00 | 890.65 | 153.80 | 120.26 | 460.45 |
|
Total Liabilities
|
13,358.00 | 936.03 | 836.65 | 641.86 | 689.81 |
Assets ($ Mln)
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
9,764.00 | 124.16 | 449.03 | 351.14 | 104.88 |
|
Current Assets
|
3,797.00 | 1,093.14 | 439.68 | 321.30 | 656.57 |
|
Total Assets
|
13,358.00 | 936.03 | 836.65 | 641.86 | 689.81 |
|
Total Debt*
|
3,918.00 | 2,493.78 | 9.42 | 93.59 | 219.21 |
|
Net Current Assets
|
1,945.00 | 202.49 | 285.87 | 201.04 | 196.12 |
Cashflow ($ Mln)
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
560.00 | -445.91 | 142.00 | -47.63 | -93.41 |
|
Cash Flow from Investing Activities
|
-279.00 | -24.49 | 69.76 | -24.76 | -0.48 |
|
Cash from Financing Activities
|
-275.00 | 359.29 | -220.37 | 28.54 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2.21 | -159.44 | 14.87 | -13.30 | -63.21 |
|
ROE (%)
|
-3.03 | 41.15 | 8.11 | -30.32 | -223.36 |
|
ROA (%)
|
-1.30 | -41.39 | 5.52 | -17.95 | -17.39 |
|
EBIT Margin (%)
|
1.61 | -89.09 | 3.17 | -30.84 | -17.57 |
|
Net Margin (%)
|
-3.96 | -100.64 | 6.61 | -31.66 | -24.68 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
11.95 | 193.38 | 16.02 | 19.19 | 56.87 |
|
EBIT Growth (%)
|
-90.61 | 5.05 | -79.11 | -57.38 | 42.45 |
|
Net Profit Growth (%)
|
-145.85 | 10.33 | -58.66 | -60.49 | 22.38 |
|
EPS Growth (%)
|
-146.42 | 12.58 | -62.44 | -52.59 | 25.75 |
|
Book Value Growth (%)
|
-3.87 | -36.90 | 12.98 | -8.64 | 9.44 |
Valuation Ratios
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-48.47 | -20.69 | 41.86 | -21.89 | -50.48 |
|
Price / Book Value
|
1.72 | -7.27 | 6.44 | 3.60 | 104.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
21.77 | -25.60 | 55.67 | -30.81 | -54.53 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.58 | -0.77 | 0.00 | 0.00 | 1.42 |
|
Short term debt to equity ratio
|
0.01 | -0.22 | 0.00 | 0.02 | 0.85 |
|
Current Ratio
|
2.05 | 1.23 | 2.86 | 2.67 | 1.43 |
|
Quick Ratio
|
1.10 | 1.17 | 2.77 | 2.38 | 1.34 |
|
Interest Coverage
|
0.36 | -6.86 | -- | -- | -37.09 |
Operating Efficiency Ratios
| Elanco Animal Health (ELAN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.95 | 36.78 | 9.26 | 15.23 | 35.73 |
|
Asset Turnover
|
0.33 | 0.41 | 0.84 | 0.57 | 0.70 |
|
Receivable days
|
70.73 | 52.44 | 28.27 | 44.72 | 104.82 |
|
Inventory Days
|
226.89 | 172.81 | 355.76 | 51.56 | 167.98 |
|
Payable days
|
45.50 | 296.14 | 785.55 | 12.52 | 529.03 |
|
Cash Conversion Cycle
|
252.12 | -70.89 | -401.52 | 83.76 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
